MPLN vs. PHR, QBTS, STGW, PINC, UPBD, LZ, TASK, VVX, GB, and FVRR
Should you be buying MultiPlan stock or one of its competitors? The main competitors of MultiPlan include Phreesia (PHR), D-Wave Quantum (QBTS), Stagwell (STGW), Premier (PINC), Upbound Group (UPBD), LegalZoom.com (LZ), TaskUs (TASK), V2X (VVX), Global Blue Group (GB), and Fiverr International (FVRR). These companies are all part of the "business services" industry.
MultiPlan vs.
MultiPlan (NYSE:MPLN) and Phreesia (NYSE:PHR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, community ranking, earnings, valuation, risk and media sentiment.
MultiPlan currently has a consensus target price of $26.25, indicating a potential downside of 10.48%. Phreesia has a consensus target price of $31.15, indicating a potential upside of 10.49%. Given Phreesia's stronger consensus rating and higher possible upside, analysts plainly believe Phreesia is more favorable than MultiPlan.
MultiPlan has a beta of 0.13, suggesting that its stock price is 87% less volatile than the S&P 500. Comparatively, Phreesia has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500.
MultiPlan has higher revenue and earnings than Phreesia. Phreesia is trading at a lower price-to-earnings ratio than MultiPlan, indicating that it is currently the more affordable of the two stocks.
In the previous week, Phreesia had 10 more articles in the media than MultiPlan. MarketBeat recorded 16 mentions for Phreesia and 6 mentions for MultiPlan. MultiPlan's average media sentiment score of 0.41 beat Phreesia's score of 0.30 indicating that MultiPlan is being referred to more favorably in the media.
Phreesia received 137 more outperform votes than MultiPlan when rated by MarketBeat users. Likewise, 68.06% of users gave Phreesia an outperform vote while only 35.71% of users gave MultiPlan an outperform vote.
Phreesia has a net margin of -20.43% compared to MultiPlan's net margin of -163.30%. MultiPlan's return on equity of -12.14% beat Phreesia's return on equity.
87.2% of MultiPlan shares are owned by institutional investors. Comparatively, 92.1% of Phreesia shares are owned by institutional investors. 8.0% of MultiPlan shares are owned by insiders. Comparatively, 5.8% of Phreesia shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Phreesia beats MultiPlan on 11 of the 18 factors compared between the two stocks.
Get MultiPlan News Delivered to You Automatically
Sign up to receive the latest news and ratings for MPLN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MultiPlan Competitors List
Related Companies and Tools
This page (NYSE:MPLN) was last updated on 2/22/2025 by MarketBeat.com Staff
